The FDA has approved the over-the-counter (OTC) sale of Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone. Narcan nasal spray has been available by prescription since 2015…
Med Lett Drugs Ther. 2023 May 1; 65(1675):72 doi:10.58347/tml.2023.1675e
The FDA has approved the over-the-counter (OTC) sale of Narcan (Emergent), a nasal spray that delivers 4 mg of the opioid antagonist naloxone. Narcan nasal spray has been available by prescription since 2015 for emergency treatment of opioid overdose. Generic formulations of Narcan have also been approved; the manufacturers of these products will be required to switch them to OTC status and amend their labeling accordingly. Kloxxado , an 8-mg naloxone nasal spray, remains available only by prescription.
The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex , the reference product, was withdrawn from the…
Med Lett Drugs Ther. 2022 Sep 5; 64(1658):141-2
The FDA has approved a generic injectable formulation of the opioid antagonist nalmefene (Purdue) for the management of known or suspected opioid overdose. Revex , the reference product, was withdrawn from the market in 2008 for commercial reasons.
The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone ( Zimhi – Adamis) for emergency treatment of opioid overdose. A single IM or SC injection of the new formulation…
Med Lett Drugs Ther. 2022 Apr 18; 64(1648):61-2
The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone ( Zimhi – Adamis) for emergency treatment of opioid overdose. A single IM or SC injection of the new formulation delivers 5 mg of naloxone; injectable formulations that deliver 0.4 mg or 2 mg of the drug have been available for years. Naloxone is also available in intranasal formulations for the same indication (see Table 1).
The FDA has approved a higher-dose intranasal naloxone formulation ( Kloxxado – Hikma) for emergency treatment of opioid overdose. A single spray of the new formulation delivers 8 mg of naloxone; a…
Med Lett Drugs Ther. 2021 Sep 20; 63(1633):151-2
The FDA has approved a higher-dose intranasal naloxone formulation ( Kloxxado – Hikma) for emergency treatment of opioid overdose. A single spray of the new formulation delivers 8 mg of naloxone; a formulation that delivers 4 mg per spray (Narcan) was approved in 2015.